Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
02 October 2024 - 10:00PM
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the
company will participate in a fireside chat at the H.C. Wainwright
8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on
Monday, Oct. 7, 2024.
The fireside chat will be webcast live and may be
accessed here or by visiting Madrigal’s website’s Investor
Relations Events page. A replay of the webcast will be available
after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom),
is a once-daily, oral, liver-directed THR-β agonist designed to
target key underlying causes of NASH. For more information, visit
www.madrigalpharma.com.
Investor ContactTina Ventura,
IR@madrigalpharma.com
Media ContactChristopher Frates,
media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Nov 2023 to Nov 2024
